Agilon Health, Inc. — Form 8-K Summary
Filing date: January 10, 2022. The Company furnished the report under Item 7.01, Regulation FD Disclosure, in connection with management meetings at the 40th Annual J.P. Morgan Healthcare Conference.
Business Context and Reporting Period
Agilon health operates a healthcare platform supporting physician partners and Medicare-related care models. This filing does not report quarterly or annual historical results; it provides management’s outlook for calendar year 2022.
Financial and Operating Metrics
- Management expects the Company to generate positive Adjusted EBITDA in 2022.
- Adjusted EBITDA is a non-GAAP measure that excludes, among other items, interest, taxes, depreciation and amortization, geography entry costs, share-based compensation, severance and certain other items.
- The filing does not provide current-period revenue, net income, cash flow, margins, debt, liquidity, or GAAP-to-non-GAAP reconciliation amounts.
Guidance and Outlook
- Management expects to reaffirm previously issued 2022 membership guidance of more than 340,000 total members live on the agilon platform.
- The membership target includes more than 260,000 Medicare Advantage members and approximately 80,000–85,000 Direct Contracting attributed beneficiaries.
- Management expects positive 2022 Adjusted EBITDA.
Material Changes Versus Prior Comparable Period
The filing does not present comparative historical financial results or identify a material change versus a prior comparable period. It indicates that previously issued 2022 membership guidance is expected to be reaffirmed.
Risks, Contingencies, and Unusual Items
The outlook is forward-looking and subject to substantial uncertainty. Identified risks include the Company’s history of net losses; increasing expenses and medical costs; difficulty achieving or maintaining profitability; execution of growth initiatives and new geographies; membership reductions; unfavorable Medicare Advantage contracts or reimbursement changes; reliance on payors, physician partners and government healthcare programs; regulatory and CMS methodology changes; COVID-19 effects; data security incidents; inaccurate diagnosis or encounter data; subsidiary funding needs; and substantial indebtedness or additional borrowing.
The Company cautions that Adjusted EBITDA may not be comparable with similarly titled measures used by other companies. No assurance is given that the membership or profitability expectations will be achieved.
Key Facts for Investors to Verify
- Whether 2022 platform membership exceeded 340,000, including the Medicare Advantage and Direct Contracting components.
- Whether the Company achieved positive 2022 Adjusted EBITDA and how the metric reconciles to GAAP net income or loss.
- Actual revenue, medical expense, cash flow, debt, liquidity and margin results, which are not provided in this filing.
- The effect of reimbursement, CMS methodology, payor contract, regulatory and medical-cost changes on future results.
- Whether the Company’s substantial indebtedness and subsidiaries’ funding requirements affect liquidity or require additional capital.